International Journal of Infection

Published by: Kowsar

In Silico B Cell and T Cell Epitopes Evaluation of lipL32 and OmpL1 Proteins for Designing a Recombinant Multi-Epitope Vaccine Against Leptospirosis

Narges Nazifi 1 , Seyyed Mojtaba Mousavi 2 , Saeedeh Moradi 3 , Amin Jaydari 4 , Mohammad Hassan Jahandar 5 and Ali Forouharmehr 2 , *
Authors Information
1 Department of Animal Science, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran
2 Department of Animal Science, Faculty of Agriculture, Lorestan University, Khorramabad, Iran
3 Department of Animal Science, Faculty of Agriculture, University of Tabriz, Tabriz, Iran
4 Department of Microbiology, Faculty of Veterinary Medicine, Lorestan University, Khorramabad, Iran
5 Department of Agriculture, Bam Branch, Islamic Azad University, Bam, IR Iran
Article information
  • International Journal of Infection: April 2018, 5 (2); e63255
  • Published Online: April 28, 2018
  • Article Type: Research Article
  • Received: October 25, 2017
  • Revised: January 28, 2018
  • Accepted: May 2, 2018
  • DOI: 10.5812/iji.63255

To Cite: Nazifi N, Mousavi S M, Moradi S, Jaydari A, Jahandar M H, et al. In Silico B Cell and T Cell Epitopes Evaluation of lipL32 and OmpL1 Proteins for Designing a Recombinant Multi-Epitope Vaccine Against Leptospirosis, Int J Infect. 2018 ; 5(2):e63255. doi: 10.5812/iji.63255.

Copyright © 2018, International Journal of Infection. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Adler B, de la Pena Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140(3-4):287-96. doi: 10.1016/j.vetmic.2009.03.012. [PubMed: 19345023].
  • 2. Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-71. [PubMed: 14652202].
  • 3. Felix SR, Hartwig DD, Argondizzo AP, Silva EF, Seixas FK, Neto AC, et al. Subunit approach to evaluation of the immune protective potential of leptospiral antigens. Clin Vaccine Immunol. 2011;18(12):2026-30. doi: 10.1128/CVI.05297-11. [PubMed: 22030369].
  • 4. Dellagostin OA, Grassmann AA, Hartwig DD, Felix SR, da Silva EF, McBride AJ. Recombinant vaccines against leptospirosis. Hum Vaccin. 2011;7(11):1215-24. doi: 10.4161/hv.7.11.17944. [PubMed: 22048111].
  • 5. Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326. doi: 10.1128/CMR.14.2.296-326.2001. [PubMed: 11292640].
  • 6. de Souza AL, Sztajnbok J, Marques SR, Seguro AC. Leptospirosis-induced meningitis and acute renal failure in a 19-month-old male child. J Med Microbiol. 2006;55(Pt 6):795-7. doi: 10.1099/jmm.0.46486-0. [PubMed: 16687602].
  • 7. Dolhnikoff M, Mauad T, Bethlem EP, Carvalho CR. Leptospiral pneumonias. Curr Opin Pulm Med. 2007;13(3):230-5. doi: 10.1097/MCP.0b013e3280f9df74. [PubMed: 17414132].
  • 8. Cullen PA, Cordwell SJ, Bulach DM, Haake DA, Adler B. Global analysis of outer membrane proteins from Leptospira interrogans serovar Lai. Infect Immun. 2002;70(5):2311-8. [PubMed: 11953365].
  • 9. Haake DA, Mazel MK, McCoy AM, Milward F, Chao G, Matsunaga J, et al. Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit synergistic immunoprotection. Infect Immun. 1999;67(12):6572-82. [PubMed: 10569777].
  • 10. Seixas FK, Fernandes CH, Hartwig DD, Conceicao FR, Aleixo JA, Dellagostin OA. Evaluation of different ways of presenting LipL32 to the immune system with the aim of developing a recombinant vaccine against leptospirosis. Can J Microbiol. 2007;53(4):472-9. doi: 10.1139/w06-138. [PubMed: 17612601].
  • 11. Cullen PA, Haake DA, Bulach DM, Zuerner RL, Adler B. LipL21 is a novel surface-exposed lipoprotein of pathogenic Leptospira species. Infect Immun. 2003;71(5):2414-21. [PubMed: 12704111].
  • 12. Dong H, Hu Y, Xue F, Sun D, Ojcius DM, Mao Y, et al. Characterization of the ompL1 gene of pathogenic Leptospira species in China and cross-immunogenicity of the OmpL1 protein. BMC Microbiol. 2008;8:223. doi: 10.1186/1471-2180-8-223. [PubMed: 19087358].
  • 13. Haake DA, Chao G, Zuerner RL, Barnett JK, Barnett D, Mazel M, et al. The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection. Infect Immun. 2000;68(4):2276-85. [PubMed: 10722630].
  • 14. Matsunaga J, Young TA, Barnett JK, Barnett D, Bolin CA, Haake DA. Novel 45-kilodalton leptospiral protein that is processed to a 31-kilodalton growth-phase-regulated peripheral membrane protein. Infect Immun. 2002;70(1):323-34. [PubMed: 11748198].
  • 15. Shang ES, Summers TA, Haake DA. Molecular cloning and sequence analysis of the gene encoding LipL41, a surface-exposed lipoprotein of pathogenic Leptospira species. Infect Immun. 1996;64(6):2322-30. [PubMed: 8675344].
  • 16. Lin X, Xiao G, Luo D, Kong L, Chen X, Sun D, et al. Chimeric epitope vaccine against Leptospira interrogans infection and induced specific immunity in guinea pigs. BMC Microbiol. 2016;16(1):241. doi: 10.1186/s12866-016-0852-y. [PubMed: 27737644].
  • 17. Branger C, Sonrier C, Chatrenet B, Klonjkowski B, Ruvoen-Clouet N, Aubert A, et al. Identification of the hemolysis-associated protein 1 as a cross-protective immunogen of Leptospira interrogans by adenovirus-mediated vaccination. Infect Immun. 2001;69(11):6831-8. doi: 10.1128/IAI.69.11.6831-6838.2001. [PubMed: 11598056].
  • 18. Forouharmehr A, Nassiry MR. B and T-cell epitopes prediction of the P40 antigen for developing mycoplasma agalactiae vaccine using Bioinformatic Tools. Genet Millennium. 2015;13(1):3954-61.
  • 19. Yousefi S, Tahmoorespur M, Sekhavati MH. B and T‐Cell epitope prediction of the OMP25 antigen for developing Brucella melitensis vaccines for sheep. Iran J Appl Animal Sci. 2015;5.
  • 20. Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, Rosales-Mendoza S. An overview of bioinformatics tools for epitope prediction: implications on vaccine development. J Biomed Inform. 2015;53:405-14. doi: 10.1016/j.jbi.2014.11.003. [PubMed: 25464113].
  • 21. Wass MN, Kelley LA, Sternberg MJ. 3DLigandSite: predicting ligand-binding sites using similar structures. Nucleic Acids Res. 2010;38(Web Server issue):W469-73. doi: 10.1093/nar/gkq406. [PubMed: 20513649].
  • 22. Arinaminpathy N, Ratmann O, Koelle K, Epstein SL, Price GE, Viboud C, et al. Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza. Proc Natl Acad Sci U S A. 2012;109(8):3173-7. doi: 10.1073/pnas.1113342109. [PubMed: 22323589].
  • 23. Jarzab A, Skowicki M, Witkowska D. [Subunit vaccines--antigens, carriers, conjugation methods and the role of adjuvants]. Postepy Hig Med Dosw (Online). 2013;67:1128-43. [PubMed: 24379254].
  • 24. Olson JK, Croxford JL, Calenoff MA, Dal Canto MC, Miller SD. A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest. 2001;108(2):311-8. doi: 10.1172/JCI13032. [PubMed: 11457884].
  • 25. Jackwood MW, Hickle L, Kapil S, Silva R, Osterrieder K, Prideaux C, et al. Vaccine development using recombinant DNA technology. Council Agric Sci Technol. 2008;38:1-11.
  • 26. Koizumi N, Watanabe H. Leptospirosis vaccines: past, present, and future. J Postgrad Med. 2005;51(3):210-4. [PubMed: 16333195].
  • 27. de Marco A. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb Cell Fact. 2009;8:26. doi: 10.1186/1475-2859-8-26. [PubMed: 19442264].
  • 28. Zamani M, Nezafat N, Negahdaripour M, Dabbagh F, Ghasemi Y. In Silico Evaluation of Different Signal Peptides for the Secretory Production of Human Growth Hormone in E. coli. Int J Peptide Res Ther. 2015;21(3):261-8. doi: 10.1007/s10989-015-9454-z.

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments